title: Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.
authors.forename: Toshitatsu
authors.initials: T
authors.lastname: Takao
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Junya
authors.initials: J
authors.lastname: Kuroda
authors.forename: Atsusi
authors.initials: A
authors.lastname: Omoto
authors.forename: Tomoko
authors.initials: T
authors.lastname: Nishimura
authors.forename: Yuri
authors.initials: Y
authors.lastname: Kamitsuji
authors.forename: Etsuko
authors.initials: E
authors.lastname: Fukiya
authors.forename: Chie
authors.initials: C
authors.lastname: Nakamura
authors.forename: Shinya
authors.initials: S
authors.lastname: Kimura
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Yoshikawa
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001202:Ascitic Fluid / Q000166:cytology; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D019288:Herpesvirus 8, Human / Q000302:isolation & purification; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D010641:Phenotype; D010996:Pleural Effusion / Q000166:cytology; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab